Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$60.83 USD
-1.03 (-1.67%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $60.78 -0.05 (-0.08%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth F Momentum D VGM
Revenue - Line of Business Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|---|
Net Sales: Transcatheter Aortic V... |
-- | 3,880 | 3,518 | 3,423 | 2,857 | 2,738 |
Net Sales: Transcatheter Mitral a... |
-- | 198 | 116 | 86 | 42 | 28 |
Net Sales: Surgical Structural He... |
-- | 999 | 893 | 889 | 762 | 842 |
Net Sales: Critical Care [$M] |
-- | 928 | 855 | 835 | 725 | 740 |
Revenue - Geographic Segments | YR Estimate | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
Net Sales: United States [$M] |
-- | 3,509 | 3,133 | 2,963 | 2,517 | 2,533 |
Net Sales: Outside of the United ... |
-- | 2,496 | 2,250 | 2,269 | 1,870 | 1,815 |
Net Sales: Europe [$M] |
-- | 1,335 | 1,175 | 1,190 | 974 | 941 |
Net Sales: Japan [$M] |
-- | 452 | 474 | 529 | 460 | 445 |
Net Sales: Rest of World [$M] |
-- | 717 | 611 | 533 | 452 | 433 |